한국지질동맥경화학회 학술대회

Evolving LDL-C management: guidelines and the role of evolocumab

Is LDL-C goal attainment enough? pitavastatin/fenofibrate in mixed dyslipidemia

Bridging guidelines and practice: strategic implementation of combination therapy in lipid management

Paving the road for optimal LDL-C management: new evidence on intensive LDL-C targeting from the Ez-PAVE trial

The role of DPP-4 inhibitors in Korean diabetes care: focusing on K-evidence

The smaller the better: rovazet

Start early: upfront combination therapy for faster LDL-C goal attainment in the CKM era

Start strong: elevating LDL-C management in ASCVD with high-dose atorvastatin plus ezetimibe

Beyond the statin, ROSUZET; start early, switch now

Be the standard ROSUZET; evidence-driven lipid management

Integrated management of hypertension and dyslipidemia for cardiovascular disease prevention

TBD (Lecture Title)

Rethinking LDL-C strategies in the aLLT era: transforming effective control into reality with leqvio cases

TBD (Lecture Title)

Clinical updates in dyslipidemia: positioning baroezet for optimal patient care

TBD (Lecture Title)

Statin therapy strategies for newly diagnosed dyslipidemia patients in clinical practice

Low-dose atorvastatin: addressing an unmet clinical need

The role of low-dose fenofibrate in the management of dyslipidemia

A new oral LDL-C lowering agent with proven CV benefit: bempedoic acid

Integrated lipid management across the CKM spectrum: from evidence to practice

TBD (Lecture Title)

Why is LDL-C control still insufficient? finding the breakthrough with leqvio cases in the aLLT era

TBD (Lecture Title)

TBD (Lecture Title)

New paradigm of initial therapy for hypertension: which patients benefit from amoprel?

Combination treatment in hypertension: why is losartan-based therapy effective?

Cutting edge care of pitavastatin with ezetimibe combination therapy

Combination treatment in hypertension: why is losartan-based therapy effective?